Skip Navigation

United States Department of Health & Human Services
line

Print Print    Download Reader PDF


 


Office for Human Research Protections (OHRP)

Gonadotropin Releasing Hormone (GnRH) Agonist Test in Disorders of Puberty


Requesting IRB:

University of Chicago

Study Summary:

The above-referenced research protocol proposes to assess whether a challenge dose of a gonadotropin releasing hormone agonist (leuprolide 10 mcg/kg) followed by serial assessments of luteinizing hormone, follicle stimulating hormone, testosterone (males) and estradiol (females), can distinguish among causes of precocious puberty and delayed puberty in children and young adults. Other procedures conducted during the study include overnight serial blood sampling for baseline sex hormone levels prior to the leuprolide injection, bone age radiographs if not done for clinical purposes within 3 months of study entry, and blood sampling for DNA testing. Serial blood draws will be done through an indwelling venous catheter using an automated pump. The proposed study will be an open label, non-randomized study in which approximately 280 children with and without a disorder of puberty will be followed over a two day period.

Funding Source:

National Center for Research Resources, National Institutes of Health

OHRP Communications

IO Communications to OHRP

IRB Communications to IO

Protocol Details

Parental Permission Documents

IRB Documents

Product Information

Clinical Research Center Documents

Other Communications and Documents

Federal Register Notices

Panel of Experts Transcripts


Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®.

Last revised: February 23, 2007

spacer

HHS Home | Questions? | Contact HHS | Accessibility | Privacy Policy | FOIA | Disclaimers

The White House | USA.gov | Helping America's Youth